Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses focusi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Wenger, Katharina J., Wagner, Marlies, You, Se-Jong, Franz, Kea, Harter, Patrick N., Burger, Michael C., Voss, Martin, Ronellenfitsch, Michael W., Fokas, Emmanouil, Steinbach, Joachim P., Bähr, Oliver
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494648/
https://ncbi.nlm.nih.gov/pubmed/28693286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6251
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados